HER2+ METASTATIC BREAST CANCER
Clinical trials for HER2+ METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2+ METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2+ METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill combo aims to shrink Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…
Matched conditions: HER2+ METASTATIC BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for brain metastases: drug combo targets hard-to-treat breast cancer
Disease control Recruiting nowThis study tests a new drug, asciminib, combined with trastuzumab in 42 adults with HER2+ breast cancer that has spread to the brain. Participants must have tried at least one prior treatment, including T-DXd and tucatinib. The goal is to see if the combination can shrink brain t…
Matched conditions: HER2+ METASTATIC BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC